Mnis+7 And Lower Limb Function In Inotersen Treatment Of Hattr
2020
INTRODUCTION Inotersen, an antisense oligonucleotide inhibitor of TTR protein production, demonstrated significant benefit versus placebo in the modified Neuropathy Impairment Score +7 neurophysiologic tests (mNIS+7) in patients with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy. This analysis assessed the mNIS+7 components by anatomic location and the Lower Limb Function (LLF) test. METHODS Adults with hATTR were randomly assigned to receive weekly doses of subcutaneous inotersen 300 mg or placebo for 65 weeks. The mNIS+7 and LLF were assessed at 35 and 66 weeks. RESULTS All major mNIS+7 components (muscle weakness, muscle stretch reflexes, sensation) and the LLF showed significant efficacy in patients receiving inotersen versus placebo; however, NIS-reflexes (upper limb), touch pressure (upper and lower limbs), and heart rate deep breathing did not show significant effects. DISCUSSION The results of this analysis reinforce the beneficial effect of inotersen on slowing neuropathy progression in patients with hATTR polyneuropathy. This article is protected by copyright. All rights reserved.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
1
Citations
NaN
KQI